Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

ABSTRACT:

Background

Current data suggest better survival in various cancer types but increased treatment toxicity in female compared with male patients. In this article, we report a pooled analysis of sex-related differences in survival outcomes and safety in patients with resectable stage III non-small-cell lung cancer (NSCLC) treated in five prospective clinical trials.

Patients and methods

Data from 499 patients included in five Swiss Group for Clinical Cancer Research (SAKK) trials for resectable stage III NSCLC were pooled. All patients were treated with three cycles of chemotherapy (cisplatin/docetaxel), either alone (n = 207, 41%), with sequential radiotherapy (n = 229, 46%) or with sequential perioperative programmed death-ligand 1 blockade (n = 62, 12%).

Results

Of 49

SUBMITTER: Frehner L 

PROVIDER: S-EPMC12651527 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature